RegulationBPC-157Compounding

HHS Will Let Pharmacies Compound Six Peptides, Including BPC-157: What the Policy Does and Doesn’t Mean

Quick answerOn October 28, 2026, HHS announced it will not enforce federal compounding rules against pharmacies that make six peptides, including BPC-157, if strict conditions are met. This is not FDA approval and not legalization. The peptides remain unapproved, human safety data are thin, and states can still restrict them.
Illustration: six vials behind a gate. Enforcement discretion opens a narrow door for compounders; it does not approve what is inside.

HHS says it will not enforce compounding rules for six peptides, under set conditions

On October 28, 2026, the Department of Health and Human Services (HHS) filed a notice titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,” scheduled for Federal Register publication on October 30 [1]. It is signed by HHS Secretary Robert F. Kennedy, Jr. and covers six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500 [1, 2].

In plain terms, HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound these six substances, as long as every listed condition is met [2]. The policy applies while FDA builds its official list of bulk substances that pharmacies may compound under section 503A of the Federal Food, Drug, and Cosmetic Act. For each peptide it stays in place until FDA addresses that peptide in a final rule [1, 2].

Holland & Knight describes the notice as an interim policy, while AJMC calls it a draft [6, 7]. Written comments were open on Regulations.gov (Docket HHS-OASH-2026-0496) until about November 13 [7].

Enforcement discretion is not approval, and it is not legalization

The notice does not add any of the six peptides to the 503A bulks list, and compounded products remain unapproved drugs [7]. HHS’s own policy text states that “Compounded drugs are not FDA-approved” and that they “may pose risks to patients” [2]. The law firm Venable summarized the point in one line: “Enforcement discretion is not legalization” [8].

Several limits follow from the documents themselves:

  • The notice says it creates no rights for any person and is not binding on HHS or the public [1].
  • It does not override state law, so state agencies can still restrict or prohibit compounding of these peptides [7].
  • HHS says it may revisit the policy, in whole or in part, if a safety signal or product quality problem emerges [2].
  • It does not extend to outsourcing facilities (503B), and it does not cover products sold as “research use only” [7, 8].

Compounders must meet ten conditions, from manufacturer to label

According to Venable’s summary, HHS will hold off on enforcement only if all ten conditions are met [8]. In short, they require that:

  • the peptide is on HHS’s list and is made only in the forms and routes HHS specifies for it;
  • the bulk substance comes from an FDA-registered facility that follows current good manufacturing practice, with a valid certificate of analysis (repackers must have validated both);
  • each product contains a single listed active ingredient;
  • the label states: “This is a compounded drug product. Not for resale.”;
  • any co-packaged device is an FDA-cleared syringe;
  • oral products come with documentation of adequate oral bioavailability in humans;
  • serious adverse events and quality problems are reported to FDA’s MedWatch and to the relevant states; and
  • the product meets the rest of the law, including the patient-specific prescription requirement and the ban on insanitary conditions [2, 8].

These are obligations on compounders. They are not a finding that the products are safe or effective.

FDA’s own reviewers recommended against listing all seven peptides they examined

The policy follows a July 23–24, 2026 meeting of FDA’s Pharmacy Compounding Advisory Committee, which considered seven peptides [3, 5]. FDA staff recommended against all seven, saying the available studies were short, small and insufficient to establish safety or effectiveness [5]. The committee nonetheless voted to recommend six, for example 8–6 with one abstention for BPC-157, and voted 7–6 against a seventh, emideltide [5]. Those votes are nonbinding [5].

FDA’s meeting page lists the uses it evaluated: BPC-157 for ulcerative colitis; TB-500 for wound healing; KPV for wound healing and inflammatory conditions; MOTS-c for obesity and osteoporosis; semax for cerebral ischemia, migraine and trigeminal neuralgia; and epitalon for insomnia [3]. HHS acknowledged that FDA’s drug center had recommended against each of the six. It described its safety concerns for TB-500, epitalon and semax as inferential or mechanistic rather than observed, and for KPV as reflecting missing information [6]. HHS’s appendix also notes that the record of human safety data is limited [2].

The human evidence is thin, and most findings come from animals

Human evidence. BPC-157 shows the gap clearly. FDA’s May 2026 briefing document found five clinical studies in the medical literature, all small: 24 healthy volunteers given an enema, 17 people with knee pain, 12 with interstitial cystitis, 2 healthy volunteers given an infusion, and a 53-person ulcerative colitis study that exists only as a meeting abstract [4]. FDA concluded there is “insufficient clinical safety information to characterize the safety profile of BPC-157,” and it found no human studies of oral, subcutaneous, nasal or transdermal use [4].

Animal evidence. The animal data are broader but still limited. In rats, FDA’s review noted that BPC-157 reduced colonic fistula size by about 40% and NSAID-induced lesions by more than 75%. The same review said dose-response relationships have not been established, and that 28-day toxicity studies in rats and dogs “appeared to be associated with clinically relevant safety signals” [4]. FDA found no carcinogenicity studies [4]. For a closer look, see our breakdown of the BPC-157 human and animal evidence.

We reviewed FDA’s BPC-157 briefing in detail. FDA posted a separate briefing document for each of the other peptides, and we have not summarized those here [3].

Medical groups and sports bodies are pushing back

At its November 2026 Interim Meeting, the American Medical Association adopted policy asking HHS, FDA and other regulators to rescind measures that ease compounding of unapproved synthetic peptides, saying such products “lack the safety, efficacy and quality evidence necessary to support their use” [10, 11]. The AMA also sent HHS a letter, dated November 11, urging it to withdraw the policy [11]. AMA trustee Ilse Levin, DO, said that allowing pharmacies to compound unapproved peptides without sufficient evidence means “patients are at increased risk of serious harm” [10].

HHS frames the policy differently. It says it aims to discourage use of “research use only” peptides from foreign manufacturers, which it says pose safety risks, by offering patients “a more controlled alternative” [2, 6].

Athletes face a separate rulebook. The U.S. Anti-Doping Agency lists BPC-157 as prohibited under the World Anti-Doping Agency’s S0 category for non-approved substances [12]. USADA’s page, last modified in August 2026, predates the HHS notice and does not mention it [12]. The HHS policy summaries we reviewed do not address anti-doping rules [7], so athletes should check with their governing body.

Product quality is the other half of the story

Quality is a stated motive for the policy. Catherine Varney, DO, of UVA Health told AJMC that gray-market peptides often contain 5% to 75% of the labeled amount and that some contain arsenic at up to ten times acceptable levels [6]. That is one physician’s account in a news article rather than a measured survey, but it matches HHS’s own concern about research-use-only imports [2]. Venable expects more scrutiny of promotional claims and telehealth prescribing, and advises against calling covered products “legalized,” “FDA approved” or broadly “FDA compliant” [8]. Readers should treat those words in marketing with caution.

What to watch next

Three things will shape what happens. First, FDA still has to decide whether to accept the committee’s recommendations and complete rulemaking on the 503A bulks list, which would replace this interim policy for each peptide [1, 5, 9]. Second, state boards of pharmacy and medicine can act independently, and the AMA says it will urge them to apply strict oversight [7, 11]. Third, HHS has reserved the right to change course if a safety signal appears [2].

For a reader trying to make sense of headlines, the useful frame is narrow: a federal enforcement posture changed, but the evidence about whether these peptides are safe and effective did not. You can follow each compound in our library: BPC-157, TB-500 and epitalon.

Frequently asked questions

Are BPC-157 and the other five peptides now legal?

Not in the sense of being approved. HHS says it will not take enforcement action against qualifying compounders if ten conditions are met, but the peptides are not on the 503A bulks list and compounded products remain unapproved drugs [7, 8]. States can still restrict them [7].

Is BPC-157 FDA-approved?

No. FDA’s reviewers recommended against placing BPC-157 on the compounding list, citing insufficient clinical safety information [4, 5].

Does the policy cover peptides sold online as “research use only”?

No. The policy does not cover research-use-only products, and HHS says it hopes to discourage their use [2, 7].

Does this change anti-doping rules for athletes?

The policy summaries we reviewed do not address anti-doping rules [7]. USADA lists BPC-157 as prohibited under WADA’s S0 category [12].

Who opposes the policy?

The American Medical Association adopted policy in November 2026 calling on HHS and FDA to rescind it and sent HHS a letter urging withdrawal [10, 11].

Sources

Every factual claim in this article comes from a source we opened and read while writing it. Where a source is a news or law-firm summary, we say so in the text.

  1. Federal Register public inspection: HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Doc. 2026-22192)
  2. HHS: 503A peptide enforcement discretion policy, Appendix B (PDF)
  3. FDA: July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting page
  4. FDA briefing document: Evaluation of BPC-157-Related Bulk Drug Substances (5/11/2026)
  5. AJMC: FDA Panel Backs 6 Peptides for Compounding
  6. AJMC: HHS Draft Policy Eases Enforcement on 6 Compounded Peptides (Oct. 29, 2026)
  7. Holland & Knight: HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides (Nov. 4, 2026)
  8. Venable: HHS Announces Interim Enforcement Discretion for Section 503A Compounding with Certain Peptide Bulk Drug Substances (Nov. 6, 2026)
  9. NCPA: FDA grants enforcement discretion to compounding six peptides (Oct. 29, 2026)
  10. AMA: Highlights from the 2026 AMA Interim Meeting
  11. AMA: Nov. 13, 2026 National Advocacy Update
  12. USADA: BPC-157, what athletes should know

Medical disclaimer

Peptides.rodeo is for education only and is not medical advice. Nothing on this site is meant to diagnose, treat, cure or prevent any disease, or to replace a consultation with a licensed physician or pharmacist.

Many compounds described here are not approved by the U.S. Food and Drug Administration for human use. Products sold “for research use only” may be mislabelled, contaminated or of unknown strength. We do not publish dosing protocols for unapproved compounds, and we do not sell, source or recommend vendors.

Evidence grades summarise published research at the date shown and can change as new studies appear. Always talk to a qualified healthcare provider before starting, stopping or changing any medication or supplement, especially if you are pregnant, nursing, have a medical condition or take other medicines. If you think you are having a medical emergency, call 911 or your local emergency number.

Written by Peptides.rodeo Editorial. This article has not been reviewed by a clinician and is not medical advice. We take no money from peptide vendors and use no affiliate links.